FCM
PTCT icon

Farallon Capital Management’s PTC Therapeutics PTCT Stock Holding History

Farallon Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-726,986
Closed -$34.9M – 112
2019
Q4 		$34.9M Hold
726,986
– – 0.24% 66
2019
Q3 		$24.6M Buy
726,986
+126,986
+21% +$5.53M 0.19% 66
2019
Q2 		$27M Sell
600,000
-100,000
-14% -$3.95M 0.18% 68
2019
Q1 		$26.3M Hold
700,000
– – 0.2% 62
2018
Q4 		$24M Buy
700,000
+280,000
+67% +$10.1M 0.18% 62
2018
Q3 		$19.7M Buy
+420,000
New +$17.4M 0.12% 66

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Farallon Capital Management's PTCT Position: Q1 2020 in Review

Farallon Capital Management sold out of PTC Therapeutics (PTCT) in Q1 2020, closing a stake of 726,986 shares — an estimated $34.9M sold.

Farallon Capital Management first reported a position in PTCT in Q3 2018 and held it in 6 quarters. The position peaked at $34.9M in Q4 2019. 203 funds tracked by Wall St. Rank hold PTCT as of Q1 2020.

  • Farallon Capital Management reported no remaining PTC Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Farallon Capital Management sold 726,986 PTC Therapeutics shares in Q1 2020, an estimated $34.9M.
  • Farallon Capital Management first reported a position in PTC Therapeutics in Q3 2018 and held it in 6 quarters.
  • Farallon Capital Management's PTC Therapeutics position peaked at $34.9M in Q4 2019.
  • 203 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2020.

Based on Farallon Capital Management's 13F filing for Q1 2020, filed 15 May 2020.